Nurix Therapeutics Appoints Paula G. O’Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
28 Mai 2024 - 1:00PM
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage
biopharmaceutical company developing targeted protein modulation
drugs designed to treat patients with cancer and inflammatory
diseases, today announced the appointments of Paula G. O’Connor,
M.D., as chief medical officer and Pasit Phiasivongsa, Ph.D., as
chief technical officer of Nurix.
“I am delighted to announce the promotions of both Paula and
Pasit, which recognize their significant and ongoing leadership in
advancing our pipeline of novel medicines and particularly in
accelerating our NX-5948 program in chronic lymphocytic leukemia
and non-Hodgkin’s lymphoma,” said Arthur T. Sands, M.D., Ph.D.,
president and chief executive officer of Nurix. “As we look ahead
to 2025 and beyond, having the right team in place is critical to
maximize speed and success in the clinic and to foster a strong
collaborative culture within Nurix.”
Dr. O’Connor joined Nurix in September 2022 and most recently
served as executive vice president and head of clinical
development. She trained as a hematologist-oncologist and has more
than 15 years of drug development expertise. Prior to joining
Nurix, Dr. O’Connor held senior level positions in clinical
development and medical affairs at Protagonist Therapeutics,
Oncopeptides, Inc., Coherus Biosciences, Medivation, Onyx, and
Genentech. Dr. O’Connor completed her fellowships in hematology,
oncology, and AIDS oncology at the combined programs of the
Massachusetts General, Brigham and Women’s, and Dana Farber Cancer
Institute. She holds a B.A. in psychology with a biology focus from
Yale University and an M.D. from Stanford University.
Dr. Phiasivongsa joined Nurix in August 2022 and most recently
served as executive vice president of technical operations. Prior
to joining Nurix, he served as senior vice president,
pharmaceutical development & manufacturing at Kronos Bio, where
he led all CMC development, manufacturing, and supply chain-related
activities. Before Kronos, Dr. Phiasivongsa served in senior CMC
leadership roles at Principia Biopharma and Tobira Therapeutics.
Early in his career, he held positions in drug discovery,
development, and manufacturing. He is listed on 32 U.S.-issued
patents and more than 40 patent applications. Dr. Phiasivongsa
earned his B.S. in biochemistry and Ph.D. in pharmaceutical and
chemical sciences from the University of the Pacific, Stockton.
About NX-5948
NX-5948 is an investigational, orally bioavailable, brain
penetrant, small molecule degrader of BTK. NX-5948 is currently
being evaluated in a Phase 1 clinical trial in patients with
relapsed or refractory B cell malignancies. Nurix has previously
reported that NX-5948 is highly potent against a range of tumor
cell lines that are resistant to current BTK inhibitor therapies,
an important consideration in heavily pretreated CLL/SLL patient
populations. Additional information on the ongoing clinical trial
can be accessed at clinicaltrials.gov (NCT05131022).
About Nurix
Nurix Therapeutics is a clinical stage biopharmaceutical company
focused on the discovery, development and commercialization of
innovative small molecules and antibody therapies based on the
modulation of cellular protein levels as a novel treatment approach
for cancer, inflammatory conditions, and other challenging
diseases. Leveraging extensive expertise in E3 ligases together
with proprietary DNA-encoded libraries, Nurix has built DELigase,
an integrated discovery platform, to identify and advance novel
drug candidates targeting E3 ligases, a broad class of enzymes that
can modulate proteins within the cell. Nurix’s drug discovery
approach is to either harness or inhibit the natural function of E3
ligases within the ubiquitin-proteasome system to selectively
decrease or increase cellular protein levels. Nurix’s wholly owned,
clinical stage pipeline includes targeted protein degraders of
Bruton’s tyrosine kinase, a B-cell signaling protein, and
inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3
ligase that regulates activation of multiple immune cell types
including T cell and NK cells. Nurix is headquartered in San
Francisco, California. For additional information
visit http://www.nurixtx.com.
Contacts:
InvestorsJason Kantor, Ph.D.Nurix
Therapeuticsir@nurixtx.com
Elizabeth Wolffe, Ph.D.Wheelhouse Life Science
Advisorslwolffe@wheelhouselsa.com
MediaAljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Nurix Therapeutics (NASDAQ:NRIX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024